Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RLMD Relmada Therapeutics, Inc.

已收盘 03-18 16:00:00 EDT

6.21

-0.24

-3.72%

盘后6.36

+0.15+2.42%

19:46 EDT

最高6.56	最低6.20	成交量145.98万
今开6.45	昨收6.45	日振幅5.50%
总市值4.55亿	流通市值3.92亿	总股本7,333万
成交额922.37万	换手率2.31%	流通股本6,315万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":6.21,"timestamp":1773864000000,"preClose":6.45,"halted":0,"volume":1459802,"hourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.21,"latestTime":"19:46 EDT","volume":3330,"amount":21020.0822,"timestamp":1773877601343,"change":0.15,"changeRate":0.024155,"amplitude":0.046586},"delay":0,"changeRate":-0.03720930232558143,"floatShares":63149200,"shares":73333622,"eps":-1.769318,"marketStatus":"已收盘","change":-0.24,"latestTime":"03-18 16:00:00 EDT","open":6.45,"high":6.555,"low":6.2,"amount":9223651.7875332,"amplitude":0.055039,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.769318,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773907200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":6.45,"preHourTrading":{"tag":"盘前","latestPrice":6.4,"preClose":6.45,"latestTime":"08:33 EDT","volume":532,"amount":3388.576128,"timestamp":1773837225963,"change":-0.05,"changeRate":-0.007752,"amplitude":0.009535},"postHourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.21,"latestTime":"19:46 EDT","volume":3330,"amount":21020.0822,"timestamp":1773877601343,"change":0.15,"changeRate":0.024155,"amplitude":0.046586},"volumeRatio":1.014333,"impliedVol":1.3197,"impliedVolPercentile":0.2988},"requestUrl":"/m/hq/s/RLMD","defaultTab":"news","newsList":[{"id":"1173035795","title":"Relmada Therapeutics股价盘前飙升27%至5.66美元 膀胱癌药物中期数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1173035795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173035795?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:44","pubTimestamp":1773056691,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics公司股价在盘前交易中大幅上涨27%，报收于5.66美元。这一显著涨幅源于其针对膀胱癌的试验性药物在中期研究阶段公布了积极数据，展现出良好的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"1110091863","title":"Relmada Therapeutics宣布超额认购1.6亿美元私募股权融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1110091863","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110091863?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:07","pubTimestamp":1773054442,"startTime":"0","endTime":"0","summary":"佛罗里达州科勒尔盖布尔斯，2026年3月9日——临床阶段生物技术公司Relmada Therapeutics, Inc.今日宣布，已签订证券购买协议，通过非公开市场进行股权投资融资，预计将为公司带来约1.6亿美元的总收益。根据协议条款，Relmada将出售合计2947.4569万股普通股，每股作价4.75美元；同时发行421.0527万份预融资权证，每份权证定价4.749美元。Relmada作为专注于肿瘤与中枢神经系统疾病创新疗法的研发企业，其核心候选药物NDV-01和sepranolone已进入中期临床试验阶段，有望填补当前治疗领域的空白。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","RLMD","BK4139"],"gpt_icon":0},{"id":"1120259669","title":"Relmada Therapeutics公司：针对BCG无应答患者的3期二线研究初步3个月结果预计于2026年底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1120259669","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120259669?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:05","pubTimestamp":1773054330,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics公司近日披露，其针对BCG无应答患者群体开展的3期二线研究，初步的3个月疗效数据预计将在2026年年底获得。这项研究是公司核心管线推进过程中的一个关键节点，其结果备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"1167411256","title":"Relmada Therapeutics公司新药NDV-01在高危NMIBC中展现76%的12个月完全缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1167411256","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167411256?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:05","pubTimestamp":1773054329,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics公司近日公布了其研究性药物NDV-01针对高危非肌层浸润性膀胱癌的积极数据。临床结果显示，该疗法在12个月的治疗周期内，达到了76%的完全缓解率，这一数据显著超越了现有标准疗法的预期效果，为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"1120820929","title":"Relmada Therapeutics公布Ndv-01治疗非肌层浸润性膀胱癌的12个月二期中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120820929","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120820929?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054182,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics, Inc. (RLMD) 已公布其候选药物Ndv-01针对非肌层浸润性膀胱癌（NMIBC）的二期临床试验为期12个月的中期分析结果。此次数据更新提供了关于该疗法在长期疗效和安全性方面的初步洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"1108541126","title":"Relmada Therapeutics公司：Leerink Partners将评级上调至“跑赢大盘”，目标价大幅提升至8美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108541126","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108541126?lang=zh_cn&edition=full","pubTime":"2026-01-23 19:57","pubTimestamp":1769169443,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，将其对生物制药公司Relmada Therapeutics, Inc.的股票评级从“与大盘持平”上调至更高的“跑赢大盘”。与此同时，该机构将其目标股价从之前的1美元大幅上调至8美元，显示出对该公司未来前景的显著看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"1134387842","title":"Relmada Therapeutics发布监管进展，确认与FDA就Ndv-01两项独立适应症注册研究设计达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1134387842","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134387842?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219346,"startTime":"0","endTime":"0","summary":"生物制药公司Relmada Therapeutics, Inc.近日公布了一项关键的监管动态。公司已确认与美国食品药品监督管理局（FDA）就其核心在研药物Ndv-01的两项独立适应症的注册研究设计达成共识。这一重要进展标志着Ndv-01的临床开发路径获得了监管机构的明确认可，为后续推进关键性注册试验奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"1141123003","title":"Relmada Therapeutics, Inc.：瑞穗证券将评级从中性上调至跑赢大盘，并将目标价提升至10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141123003","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141123003?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:05","pubTimestamp":1763543112,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics, Inc.：瑞穗证券将评级从中性上调至跑赢大盘，并将目标价提升至10美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"1194870725","title":"Relmada Therapeutics公布1亿美元的普通股和预付认股权证承销发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1194870725","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194870725?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:10","pubTimestamp":1762258209,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics公布1亿美元的普通股和预付认股权证承销发行定价","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"1140261092","title":"Relmada宣布FDA反馈支持Ndv-01在非肌肉侵袭性膀胱癌的两条独立可接受注册研究路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1140261092","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140261092?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:04","pubTimestamp":1762257852,"startTime":"0","endTime":"0","summary":"Relmada宣布FDA反馈支持Ndv-01在非肌肉侵袭性膀胱癌的两条独立可接受注册研究路径","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"1138412862","title":"Relmada Therapeutics, Inc.任命知名泌尿肿瘤学家Max Kates医生加入临床顾问委员会，支持NDV-01药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1138412862","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138412862?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:31","pubTimestamp":1759836684,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics, Inc.宣布任命知名泌尿肿瘤学家Max Kates医生加入临床顾问委员会，以支持NDV-01药物的开发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2511522076","title":"Relmada Therapeutics, Inc.盘中异动 股价大涨5.15%报0.321美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511522076","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511522076?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:15","pubTimestamp":1739463325,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日00时15分，Relmada Therapeutics, Inc.股票出现异动，股价快速拉升5.15%。截至发稿，该股报0.321美元/股，成交量23.9588万股，换手率0.79%，振幅8.76%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.03%。其相关个股中，Edesa Biotech, Inc.、Dominari Holdings Inc.、Pliant Therapeutics, Inc.涨幅较大，Edesa Biotech, Inc.、Tc Biopharm  Plc、Genprex, Inc.较为活跃，换手率分别为2707.91%、1167.95%、162.97%，振幅较大的相关个股有Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为95.15%、92.30%、42.61%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214001525988440c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214001525988440c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","RLMD"],"gpt_icon":0},{"id":"2509253236","title":"Relmada Therapeutics, Inc.盘中异动 下午盘急速上涨5.79%报0.360美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509253236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509253236?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:00","pubTimestamp":1738785610,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时00分，Relmada Therapeutics, Inc.股票出现波动，股价快速拉升5.79%。截至发稿，该股报0.360美元/股，成交量23.2465万股，换手率0.77%，振幅9.23%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.42%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Transcode Therapeutics, Inc.、Invivyd, Inc.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4655.15%、2388.12%、1767.20%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为132.24%、99.51%、75.00%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020604001196193c08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020604001196193c08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","RLMD"],"gpt_icon":0},{"id":"2506930526","title":"Relmada Therapeutics, Inc.盘中异动 早盘股价大跌5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506930526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506930526?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:56","pubTimestamp":1737989773,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时56分，Relmada Therapeutics, Inc.股票出现波动，股价急速跳水5.94%。截至发稿，该股报0.366美元/股，成交量4.16万股，换手率0.14%，振幅2.83%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.97%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Evaxion Biotech As、Hepion Pharmaceuticals, Inc.较为活跃，换手率分别为1332.79%、160.28%、75.97%，振幅较大的相关个股有阿诺医药、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为98.54%、85.35%、65.16%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225614a231700d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225614a231700d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2503257468","title":"Relmada Therapeutics, Inc.盘中异动 早盘股价大涨7.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503257468","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503257468?lang=zh_cn&edition=full","pubTime":"2025-01-14 22:32","pubTimestamp":1736865126,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日22时32分，Relmada Therapeutics, Inc.股票出现异动，股价大幅上涨7.72%。截至发稿，该股报0.435美元/股，成交量1.9783万股，换手率0.07%，振幅0.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Eterna Therapeutics Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大，Soligenix, Inc.、Phio Pharmaceuticals Corp.、Eterna Therapeutics Inc.较为活跃，换手率分别为348.45%、218.68%、112.38%，振幅较大的相关个股有Eterna Therapeutics Inc.、Fate Therapeutics, Inc.、Renovaro Inc.，振幅分别为32.98%、14.73%、13.58%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114223206abaaac8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114223206abaaac8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2503588952","title":"Relmada Therapeutics, Inc.盘中异动 股价大涨7.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503588952","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503588952?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778704,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分，Relmada Therapeutics, Inc.股票出现波动，股价大幅上涨7.74%。截至发稿，该股报0.444美元/股，成交量1.9179万股，换手率0.06%，振幅0.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.01%。其相关个股中，Salarius Pharmaceuticals, Inc.、Phio Pharmaceuticals Corp.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为2580.35%、1596.43%、389.66%，振幅较大的相关个股有Verrica制药、天境生物、Okyo Pharma Ltd Com Npv ，振幅分别为106.80%、106.67%、101.76%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223144aba93070&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223144aba93070&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","RLMD"],"gpt_icon":0},{"id":"2495626619","title":"Relmada Therapeutics, Inc.盘中异动 股价大跌5.14%报0.435美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495626619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495626619?lang=zh_cn&edition=full","pubTime":"2024-12-31 22:40","pubTimestamp":1735656047,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日22时40分，Relmada Therapeutics, Inc.股票出现波动，股价快速下跌5.14%。截至发稿，该股报0.435美元/股，成交量30.8973万股，换手率1.02%，振幅9.83%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。其相关个股中，知临集团、Onconetix, Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Onconetix, Inc.、知临集团、Eyenovia, Inc.较为活跃，换手率分别为1023.00%、843.14%、163.24%，振幅较大的相关个股有Onconetix, Inc.、知临集团、Eyenovia, Inc.，振幅分别为125.86%、119.56%、47.48%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231224048ab99843f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231224048ab99843f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","RLMD","LENZ"],"gpt_icon":0},{"id":"2493176545","title":"Relmada Therapeutics, Inc.盘中异动 早盘急速上涨8.57%报0.394美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493176545","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493176545?lang=zh_cn&edition=full","pubTime":"2024-12-23 22:32","pubTimestamp":1734964342,"startTime":"0","endTime":"0","summary":"北京时间2024年12月23日22时32分，Relmada Therapeutics, Inc.股票出现异动，股价大幅拉升8.57%。截至发稿，该股报0.394美元/股，成交量11.054万股，换手率0.37%，振幅2.76%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Traws Pharma, Inc.、Rapt Therapeutics, Inc.、Gt Biopharma, Inc.涨幅较大，Phio Pharmaceuticals Corp.、Gt Biopharma, Inc.、Traws Pharma, Inc.较为活跃，换手率分别为663.20%、440.93%、288.06%，振幅较大的相关个股有Traws Pharma, Inc.、Gt Biopharma, Inc.、Neurosense Therapeutics Ltd.，振幅分别为36.65%、33.81%、19.04%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223223224a2050acc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223223224a2050acc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2490868978","title":"Relmada Therapeutics, Inc.盘中异动 早盘快速下挫5.87%报0.442美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490868978?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:31","pubTimestamp":1733927461,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时31分，Relmada Therapeutics, Inc.股票出现波动，股价大幅下跌5.87%。截至发稿，该股报0.442美元/股，成交量6.6861万股，换手率0.22%，振幅0.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Candel Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Synlogic, Inc.涨幅较大，Silexion Therapeutics Corp、Candel Therapeutics, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为365.60%、100.62%、97.27%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、Synlogic, Inc.、Bioline Rx Ltd，振幅分别为7.69%、6.21%、5.03%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223101ab6fc977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223101ab6fc977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","RLMD"],"gpt_icon":0},{"id":"2488197547","title":"Relmada Therapeutics, Inc.盘中异动 大幅下挫76.50%报0.651美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488197547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488197547?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:32","pubTimestamp":1733322732,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日22时32分，Relmada Therapeutics, Inc.股票出现波动，股价快速跳水76.50%。截至发稿，该股报0.651美元/股，成交量392.623万股，换手率13.01%，振幅2.74%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Cyclerion Therapeutics, Inc.、Heron Therapeutics, Inc.、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Cyclerion Therapeutics, Inc.、Can Fite Biopharma Ltd、Windtree Therapeutics, Inc.较为活跃，换手率分别为1238.61%、191.03%、111.34%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Heron Therapeutics, Inc.、Eterna Therapeutics Inc.，振幅分别为53.42%、27.97%、13.56%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204223212a26c5dfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204223212a26c5dfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RLMD","LENZ","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.relmada.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":0.7339},{"period":"3month","weight":0.6085},{"period":"6month","weight":2.9091},{"period":"1year","weight":20.8867},{"period":"ytd","weight":0.3354}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Relmada Therapeutics, Inc.根据内华达州法律注册成立。该公司是一家公开上市的临床阶段生物技术公司，在对其开发项目进行审查后已进行战略重心转移。它正通过许可引进和收购来推进其研发管线，其中包括一个处于2期阶段的膀胱癌候选药物和一个准备进入2b期的用于神经和代谢疾病的神经类固醇。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.038602},{"month":2,"riseRate":0.625,"avgChangeRate":0.084231},{"month":3,"riseRate":0.625,"avgChangeRate":0.030252},{"month":4,"riseRate":0.714286,"avgChangeRate":0.052877},{"month":5,"riseRate":0.5,"avgChangeRate":0.173917},{"month":6,"riseRate":0.125,"avgChangeRate":-0.123736},{"month":7,"riseRate":0.75,"avgChangeRate":0.083628},{"month":8,"riseRate":0.5,"avgChangeRate":0.100482},{"month":9,"riseRate":0.875,"avgChangeRate":0.190291},{"month":10,"riseRate":0.5,"avgChangeRate":0.106137},{"month":11,"riseRate":0.375,"avgChangeRate":0.05543},{"month":12,"riseRate":0.5,"avgChangeRate":0.004602}],"exchange":"NASDAQ","name":"Relmada Therapeutics, Inc.","nameEN":"Relmada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Relmada Therapeutics, Inc.,RLMD,Relmada Therapeutics, Inc.股票,Relmada Therapeutics, Inc.股票老虎,Relmada Therapeutics, Inc.股票老虎国际,Relmada Therapeutics, Inc.行情,Relmada Therapeutics, Inc.股票行情,Relmada Therapeutics, Inc.股价,Relmada Therapeutics, Inc.股市,Relmada Therapeutics, Inc.股票价格,Relmada Therapeutics, Inc.股票交易,Relmada Therapeutics, Inc.股票购买,Relmada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}